EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8
To Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
NASDAQ: ACIU | Annual General Meeting – June 11, 2026 Pioneering Precision Prevention Targeted Therapeutics for Neurodegenerative Diseases
Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
First Quarter 2026 Financial and Corporate Updates
Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Announces Amendment to Morphomer® Tau License and Collaboration Agreement
Reports Full Year 2025 Financial Results and Provides a Corporate Update
Announces First Participant Dosed in Phase 1 Clinical Trial of ACI-19764
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload